Literature DB >> 8815571

The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study.

J D Douketis1, J S Ginsberg, R F Burrows, E K Duku, C E Webber, P Brill-Edwards.   

Abstract

We performed a prospective matched cohort study to investigate the effects of long-term (> 1 month) heparin therapy on lumbar spine bone density. Twenty-five women who received heparin during pregnancy, and 25 matched controls underwent dual photon absorptiometry of the lumbar spine in the post-partum period. Zero of 25 heparin-treated patients developed fractures. Heparin-treated patients had a 0.082 g/cm2 lower bone density compared to untreated controls, which is clinically and statistically significant (p = 0.0077). There were 6 matched pairs in which only the heparin-treated patient had a bone density below 1.0 g/cm2, compared to only one pair in which only the control patient had a bone density below this level (p = 0.089). The correlation coefficients of the difference in bone density in each matched pair, and the duration of heparin therapy, the mean daily dose, and the total dose of heparin were 0.042, - 0.015, and 0.021, respectively; none of these values is statistically significant. We conclude: 1) long-term heparin therapy was associated with a significant reduction in bone density, although fractures are uncommon, 2) there was no significant correlation between lumbar bone density and the dose or duration of heparin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8815571

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Medication-induced osteoporosis: screening and treatment strategies.

Authors:  Keshav Panday; Amitha Gona; Mary Beth Humphrey
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

Review 3.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

4.  A longitudinal study of the effect of heparin thromboprophylaxis during pregnancy on maternal bone metabolism.

Authors:  O Ogueh; M R Johnson; A Benjamin
Journal:  Obstet Med       Date:  2009-11-30

Review 5.  Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation.

Authors:  Usman Baber; Sarina van der Zee; Valentin Fuster
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

Review 6.  Antithrombotic therapy for prosthetic valves: routine treatment and special considerations.

Authors:  A M Al-Ahmad; D Hartnett-Daudelin; D N Salem
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 7.  Anticoagulant therapy in special circumstances.

Authors:  T G DeLoughery
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

8.  Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.

Authors:  Kyeongsoon Park; Yoo-Shin Kim; Gee Young Lee; Rang-Woon Park; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

9.  Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma.

Authors:  Kyeongsoon Park; Gee Young Lee; Rang-Woon Park; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2007-07-11       Impact factor: 4.200

10.  Treatment of Venous Thromboembolism in Pregnancy.

Authors:  Wee Shian Chan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.